

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10628 U.S. PTO  
10/059395  
01/31/02

Application of: Young et al.

Atty. Docket No.: PZ004G22YP1D1

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: 87 Human Secreted Proteins

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR 1.97**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-CX listed on the attached Form PTO/SB/08A.

Copies of references AA-AI and AQ-CX were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application No. 09/154,707, filed September 17, 1998, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. 1.98(d). The Examiner is directed to U.S. Patent Application No. 09/154,707, for copies of references AA-AI and AQ-CX

Copies of references AA-AP were submitted by Applicants in connection with U. S. Patent Application No. 09/983,966, filed 10/26/2001 to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. 1.98(d). The Examiner is directed to U.S. Patent Application No. 09/983,966, for copies of references AA-AP; all of which the instant application claims priority to under 35 U.S.C. § 120. Pursuant to 37 C.F.R. 1.98(d), the Examiner is directed to the files of the above applications for copies of the references as noted above.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Respectfully submitted,

Dated: JANUARY 31, 2002

  
Janet M. Martineau (Reg. No. 46,903)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: 301-315-2723

Enclosure(s)  
KKH/JMM/KC/mlm/lcc

Please type a plus sign (+) inside this box ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Herewith (January 30, 2002)
				First Named Inventor	Young, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	PZ004G22YP1D1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	AA	5,536,637		Jacobs	07-16-96
	AB	5,871,970		Hillman, et al.	02-16-99
	AC	5,976,801		Bandman, et al.	11-02-99

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>			
	AD	WO	90/14432	Genetics Institute, Inc.	11-29-90	
	AE	WO	96/17925	Immunex Corporation	06-13-96	
	AF	WO	97/04097	Genetics Institute, Inc.	02-06-97	
	AG	WO	97/07198	Genetics Institute, Inc.	02-27-97	
	AH	WO	99/07849	Incyte Pharmaceuticals, Inc.	02-18-99	
	AI	WO	98/44114	Incyte Pharmaceuticals, Inc.	10-08-98	
	AJ	WO	98/42738	Human Genome Sciences Inc.	10-01-98	
	AK	WO	99/63088	Genentech	12-09-99	
	AL	WO	00/53753	Genentech	01-05-00	
	AM	WO	00/73452	Genentech	09-14-00	
	AN	WO	00/73454	Genentech	12-07-00	
	AO	WO	01/05972	Genentech	01-25-01	
	AP	WO	01/09327	Genentech	02-08-01	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol as indicated on the document under WPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the accuracy of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

13838 U.S. PTO  
10/059395  
02/31/02

Please type a plus sign (+) inside this box ☐

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	AQ	Genbank Accession No. D30965 (1995)
	AR	Genbank Accession No. H08241 (1995)
	AS	Genbank Accession No. D31176 (1995)
	AT	Genbank Accession No. H04035 (1995)
	AU	Genbank Accession No. H73236 (1995)
	AV	Genbank Accession No. H74164 (1995)
	AW	Genbank Accession No. R34003 (1995)
	AX	Genbank Accession No. R66471 (1995)
	AY	Genbank Accession No. R88485 (1995)
	AZ	Genbank Accession No. AA003043 (1996)
	BA	Genbank Accession No. AA028649 (1996)
	BB	Genbank Accession No. AA041304 (1996)
	BC	Genbank Accession No. AA041328 (1996)
	BD	Genbank Accession No. W14868 (1996)
	BE	Genbank Accession No. W41218 (1996)
	BF	Genbank Accession No. W42572 (1996)
	BG	Genbank Accession No. W56939 (1996)
	BH	Genbank Accession No. W64383 (1996)
	BI	Genbank Accession No. W70681 (1996)
	BJ	Genbank Accession No. W70707 (1996)
	BK	Genbank Accession No. W91002 (1996)
	BL	Genbank Accession No. W95460 (1996)
	BM	Genbank Accession No. W95567 (1996)
	BN	Genbank Accession No. W98300 (1996)
	BO	Genbank Accession No. W98572 (1996)
	BP	Genbank Accession No. AA232452 (1997)
	BQ	Genbank Accession No. AA239568 (1997)
	BR	Genbank Accession No. AA405402 (1997)
	BS	Genbank Accession No. AA427487 (1997)
	BT	Genbank Accession No. AA427646 (1997)
	BU	Genbank Accession No. AA456267 (1997)
	BV	Genbank Accession No. AA594137 (1997)
	BW	Genbank Accession No. AA688740 (1997)
	BX	Genbank Accession No. AAC53316 (1997)
	BY	Genbank Accession No. AD001502 (1997)
	BZ	Genbank Accession No. W12808 (1997)
	CA	Genbank Accession No. AA788855 (1998)
	CB	Genbank Accession No. AAC17216 (1998)
	CD	Genbank Accession No. CAA16492 (1998)
	CE	Genbank Accession No. A1341112 (1999)

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the accuracy of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

10/059395  
02/31/02

Please type a plus sign (+) inside this box ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

CF	Genbank Accession No. AI478733 (1999)
CG	Genbank Accession No. AI797684 (1999)
CH	Genbank Accession No. AA875665 (1999)
CI	Genbank Accession No. BAA07670 (1999)
CJ	Genbank Accession No. CAA05100 (1999)
CK	Genbank Accession No. D42073 (1999)
CL	Genseq Accession No. Y00916 (1999)
CM	Genseq Accession No. Y00917 (1999)
CN	Genseq Accession No. Y11533 (1999)
CO	Genseq Accession No. Y13382 (1999)
CP	Genbank Accession No. BAA07896 (2000)
CQ	Genseq Accession No. Y53640 (2000)
CR	Stryer, Bio. Chem., 16-17 (1988)
CS	Ozawa et al., J. of Biol. Chem., 268(1):699-705 (1993)
CT	Ozawa, J. Biochem., 118:154-160 (1995)
CU	Zubay, Biol. Chem., p. 7 (1983)
CV	Biochemistry, Lehninger, pp. 67-73, (1970)
CW	Critical Synergy: The Biotechnology Industry and Intellectual Property Protection, Biotechnology Industry Organization, pp. 75 and 100-107 (1994)
CX	Jacobs, et al., J. of Cell. Biochem. Suppl., p. 19, Abstract No. C1-207 (1995)

Examiner Signature	Date Considered
-----------------------	--------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

10/059395  
01/31/02